In the Nordics, where medtech innovation often emerges from tight collaborations between universities, hospitals, and deep‑tech investors, few companies have captured attention as rapidly as Finland’s Solid‑IO.
Born in early 2025 as a University of Helsinki spin‑out, founded by Noora Hujala (CEO) and Dr Heidi Haikala (CSO), the company aims to shift cancer care away from probabilistic guesswork and toward treatment pathways tailored to each patient’s tumour biology. Its proposition is as ambitious as it is timely: a tumour‑on‑chip diagnostic platform capable of predicting, in real time, how an individual patient’s cancer will respond to immunotherapies or drug combinations.
Their pitch lands in a healthcare landscape desperate for tools that solve the enduring bottlenecks in immuno‑oncology: biomarker unreliability, high trial attrition, and the economic drain of ineffective therapies. But as with any technology claiming to “end guesswork”, a closer look is essential, not only at the innovation itself, but the evidence, the patents, the scientific lineage, the competitive terrain, and the barriers that lie between promising prototypes and clinical adoption.
This article tries to examine these dimensions in full, incorporating a focused patent analysis and drawing on all available public information from Solid‑IO and its research partners.
A Research Lineage
Understanding Solid‑IO’s credibility requires understanding its academic ancestry. The company originates from a research programme led by Dr Heidi Haikala at the University of Helsinki, where extensive work has been done on understanding tumour–immune system interactions, immunotherapy variability, and the need for patient‑specific response models.
According to the Helsinki Innovation Services profile, Haikala’s team had long been attempting to solve the mismatch between preclinical drug behaviour and patient‑specific responses, noting that thousands of immuno‑oncology drugs move through pipelines with limited predictive tools to guide stratification.
Solid‑IO’s foundation was thus more than entrepreneurial opportunism, it was a direct extension of an academic recognition: the immunotherapy field is drowning in experimental therapies but starving for reliable prediction mechanisms.
This background explains the company’s early traction in Finland’s innovation ecosystem. Funding from Nordic Science Investments, BSV Ventures, Helsinki University Funds, and a private European investor was secured in February 2025, providing an €800,000 boost.
Tumour Microenvironment
Solid‑IO’s tumour‑on‑chip device models a patient’s own tumour microenvironment, complete with cellular, stromal, and immune components. According to multiple reports, the platform produces real‑time, high‑accuracy readouts of how cancers respond to specific immunotherapies and combination treatments.
Essentially, the system miniaturises the tumour environment into a controlled microfluidic chip, enabling clinicians or researchers to test therapeutic responses outside the patient’s body, but under conditions that mimic its biological reality.
The potential benefits span three domains:
- Clinical decision support
Treatment plans would be guided by how a patient’s cancer actually behaves, not by statistical likelihoods.
“Every cancer patient deserves a treatment plan based on their unique biology,” said Hujala in several reports. - Drug development acceleration
Pharmaceutical trials could use the chips for more accurate patient stratification, biomarker validation, and treatment‑response modelling, all of which can shorten trial timelines. - Reduced toxic, ineffective therapies
Solid‑IO’s model could prevent patients from receiving high‑cost immunotherapies unlikely to work, thereby cutting unnecessary treatment costs and limiting harmful side‑effects.
Focused Patent Landscape
A search for Solid‑IO’s patent footprint reveals no formal patents directly assigned to the company in public Espacenet‑linked searches. However, the research group behind Solid‑IO filed a patent application in summer 2023, long before the formal company launch. The application covers methods for testing and growing cells more rapidly and accurately on tumour‑on‑chip platforms, a claim central to Solid‑IO’s technological edge.
This early filing indicates strategic foresight, but the absence of further patents raises important questions:
1. Is the company relying on trade secrets?
Microfluidic architecture, biomaterial composition, and flow‑control systems can be protected as proprietary know‑how rather than patents.
2. Is the technology still evolving too rapidly to freeze into patent claims?
Academic spin‑outs often delay patents until data stabilises.
3. Is there a risk of competitive encroachment?
The organ‑on‑chip field is crowded with patents from major players like MIT‑adjacent spinouts, EU research consortia, and device‑heavy firms across the Netherlands, the US, and Asia. Without a wider patent perimeter, Solid‑IO may face challenges defending its novel propositions as the market matures.
Given the company’s declared ambitions, one might expect additional filings soon, particularly covering immune–tumour interaction modelling, real‑time microenvironmental sensing, or AI‑enhanced response prediction, areas heavily explored in adjacent academic literature.
Competition
Solid‑IO is not alone in the Nordic push toward organ‑on‑chip oncology. Oulu‑based Finnadvance, for instance, develops the AKITA platform, a high‑throughput organ‑on‑chip system also used for immuno‑oncology applications. Their model recently demonstrated its ability to study immune‑cell recruitment into kidney tumours using engineered oncolytic viruses.
Where Finnadvance emphasises throughput and scalability, Solid‑IO differentiates through deep patient specificity. Both approaches address genuine industry needs, but if Finnadvance’s traction accelerates, Solid‑IO will face competition not only for market share but also for hospital collaborations, pharma partnerships, and regulatory mindshare.
Solid‑IO’s proposition is powerful, but several challenges remain unresolved:
1. Clinical validation is slow, expensive, and bureaucratically complex
No tumour‑on‑chip platform has yet achieved widespread hospital adoption or regulatory approval as a clinical diagnostic. Solid‑IO will need to demonstrate reproducibility across cancer types and clinical sites—arguably the hardest part of commercialisation.
2. AI integration complicates regulation
Solid‑IO references the use of AI for interpreting tumour microenvironment data. This places future versions of the platform squarely in the evolving category of software‑as‑a‑medical‑device (SaMD), subject to stringent oversight.
3. Hospitals resist workflow disruptions
To win adoption, Solid‑IO must prove its chips are easy to use, compatible with existing lab infrastructure, and clinically actionable within tight timeframes.
4. The race against biomarker‑based diagnostics
While biomarkers are imperfect, AI‑enhanced histopathology and multiomic profiling are advancing rapidly. Solid‑IO’s value proposition must outperform these parallel technologies.
5. Scaling biological systems is inherently messy
Solid‑IO’s system depends on maintaining living primary tumour and immune cells. Batch variability, contamination risk, and inter‑patient heterogeneity all threaten consistency.
In other words: the science is strong, the ambition is worthy, but the path to routine clinical use remains steep.
The Strategic Upside
Solid‑IO is emblematic of a broader Nordic trend: highly specialised medtech born from academic excellence, leveraging strong public healthcare systems as testbeds for new oncology tools.
If Solid‑IO succeeds, the Nordics may achieve:
- earlier integration of precision diagnostics into care pathways
- stronger local pharma‑device collaborations
- leadership in organ‑on‑chip standards and regulatory frameworks
- attraction of international capital to deep‑tech oncology ventures
The company’s €800k seed round is small by global standards, but it sits within a region that has often managed to turn modest funding into disproportionately large clinical impact.
A Technology at the Threshold
Solid‑IO represents one of the most compelling diagnostic innovations emerging from Finland’s medtech ecosystem. Its vision, placing a patient’s tumour on a chip to guide therapy with unprecedented fidelity, addresses one of oncology’s most expensive and emotionally devastating problems: uncertainty.
The company’s scientific roots are solid, its early funding is promising, and its platform sits at the front edge of immuno‑oncology innovation. Yet the road ahead requires overcoming significant challenges in clinical validation, regulatory acceptance, and competitive differentiation.
Whether Solid‑IO becomes a pillar of future cancer diagnostics or remains one of many ambitious contenders will depend on how it navigates those hurdles. What is clear is that the Nordic region is once again positioning itself as a serious player in the global race toward personalised medicine.
References (APA)
ArcticStartup. (2025). Finnish startup Solid IO raises funding to develop tumour‑on‑chip technology for precision oncology. Retrieved from ArcticStartup. [arcticstartup.com]
Helsinki Innovation Services. (n.d.). SOLID‑IO helps develop new immunotherapies for cancer patients faster and cheaper. Retrieved from University of Helsinki. [helsinki.fi]
Nordic Science Investments. (2025). Solid IO raises 800,000 € – Funding round. Retrieved from NSI. [nordscience.fi]
Tech.eu. (2025). Solid IO secures €800k to transform cancer treatment with tumour‑on‑chip technology. Retrieved from Tech.eu. [tech.eu]
TechNews180. (2025). Solid IO secures €800k to advance tumour‑on‑chip cancer treatment. Retrieved from TechNews180. [technews180.com]
AIN. (2025). Solid IO secures €800k to advance patient‑specific tumour‑on‑chip technology. Retrieved from AIN. [en.ain.ua]
Solid‑IO. (2025). Solid IO raises €800,000 to eliminate guesswork in cancer care. Retrieved from Solid‑IO. [solid-io.com]
Finnadvance / OuluHealth. (2025). Finnadvance’s organ‑on‑chip platform advances immuno‑oncology therapies.Retrieved from OuluHealth. [ouluhealth.fi]
Crunchbase. (n.d.). Solid IO company profile. Retrieved from Crunchbase. [crunchbase.com]
Photo: Solid IO
